Agitg Nabnec: A Randomised Phase II Study of NAB-Paclitaxel in Combination With Carboplatin as First-Line Treatment of Gastrointestinal Neuroendocrine Carcinomas

Khasraw, Mustafa; Lipton, Lara; Hofman, Michael; Gebski, Val; Gill, Anthony; Markman, Ben; Yip, Sonia; Gibbs, Emma; Karapetis, Chris; Pavlakis, Nick; Wong, Shu Fen; Ransom, David; Sjoquist, Katrin; Michael, Michael; Rayani, Uzma; Simes, John; Chantrill, Lorraine

Agitg Nabnec: A Randomised Phase II Study of NAB-Paclitaxel in Combination With Carboplatin as First-Line Treatment of Gastrointestinal Neuroendocrine Carcinomas

conference contribution

posted on 2024-06-19, 00:51 authored by Mustafa Khasraw, Lara Lipton, Michael Hofman, Val Gebski, Anthony Gill, Ben Markman, Sonia Yip, Emma Gibbs, Chris Karapetis, Nick Pavlakis, Shu Fen Wong, David Ransom, Katrin Sjoquist, Michael Michael, Uzma Rayani, John Simes, Lorraine Chantrill

Agitg Nabnec: A Randomised Phase II Study of NAB-Paclitaxel in Combination With Carboplatin as First-Line Treatment of Gastrointestinal Neuroendocrine Carcinomas

History

Volume

13

Pagination

166-167

ISSN

1743-7555

eISSN

1743-7563

Language

English

Author URL

http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000413954500262&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=a045e4b2bb1f2b747c68c720ec8913b7

Publication classification

E3 Extract of paper

Title of proceedings

ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY

Publisher

WILEY

Usage metrics

Keywords

Science & Technology Life Sciences & Biomedicine Oncology 111299 Oncology and Carcinogenesis not elsewhere classified 3211 Oncology and carcinogenesis

Agitg Nabnec: A Randomised Phase II Study of NAB-Paclitaxel in Combination With Carboplatin as First-Line Treatment of Gastrointestinal Neuroendocrine Carcinomas

History

Volume

Pagination

ISSN

eISSN

Language

Author URL

Publication classification

Title of proceedings

Publisher

Usage metrics

Categories

Keywords

Licence

Exports